ACTR-61. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

BACKGROUND: Like most proliferating tumors, GBM relies heavily on accurate DNA repair for maintenance of genome stability. Dysfunction in repair of both single and double strand DNA breaks by PARP inhibition and impairment of homologous recombination, respectively, would be synthetically lethal. In...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Arrillaga-Romany, Isabel, Sahebjam, Solmaz, Picconi, David, Campian, Jian, Giglio, Pierre, Drappatz, Jan, Aiken, Robert, Villano, John, Lee, Eudocia, Welch, Mary, Ellingson, Benjamin, Ney, Douglas, Becker, Kevin, Muzikansky, Alona, Das, Biswajit, Swisher, Elizabeth, Nixon, Andrew, Karlovich, Chris, Mickey Williams, P, Percy Ivy, S, Batchelor, Tracy, Gerstner, Elizabeth
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Adult Clinical Trials - Non-Immunologic
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847111/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.103
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares